ArticleRheumatology advances in practice2022

Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany.

Hans-Peter Tony et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.